# ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)

> **NCT04432272** · PHASE2 · TERMINATED · sponsor: **Corewell Health East** · enrollment: 71 (actual)

## Conditions studied

- COVID-19
- Severe Acute Respiratory Syndrome (SARS)
- Coronavirus Infections

## Interventions

- **BIOLOGICAL:** COVID-19 convalescent plasma

## Key facts

- **NCT ID:** NCT04432272
- **Lead sponsor:** Corewell Health East
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-16
- **Primary completion:** 2020-11-13
- **Final completion:** 2020-11-28
- **Target enrollment:** 71 (ACTUAL)
- **Why stopped:** The EUA for CCP was updated by FDA, stipulating that only high titer units be used. This study required untitered units. The study became infeasible
- **Last updated:** 2022-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04432272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04432272, "ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04432272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*